×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BEAM – beam therapeutics inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BEAM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/13
06:36 am
beam
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
Low
Report
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
1/12
12:51 pm
beam
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]
Low
Report
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]
1/11
05:13 pm
beam
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]
High
Report
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]
1/11
05:00 pm
beam
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
High
Report
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
1/11
01:03 am
beam
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at Wall Stree
High
Report
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at Wall Stree
1/9
06:10 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.
1/7
03:00 am
beam
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
1/5
12:43 pm
beam
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure [Yahoo! Finance]
Low
Report
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
07:01 am
beam
Form 8-K Beam Therapeutics Inc. For: Jan 11
High
Report
Form 8-K Beam Therapeutics Inc. For: Jan 11
1/5
04:16 pm
beam
Form 4 Beam Therapeutics Inc. For: Dec 31 Filed by: Emany Sravan Kumar
Medium
Report
Form 4 Beam Therapeutics Inc. For: Dec 31 Filed by: Emany Sravan Kumar
1/5
04:13 pm
beam
Form 4 Beam Therapeutics Inc. For: Dec 31 Filed by: Bellon Christine
Medium
Report
Form 4 Beam Therapeutics Inc. For: Dec 31 Filed by: Bellon Christine
1/5
04:11 pm
beam
Form 4 Beam Therapeutics Inc. For: Dec 31 Filed by: Simon Amy
Medium
Report
Form 4 Beam Therapeutics Inc. For: Dec 31 Filed by: Simon Amy
12/11
04:31 pm
beam
Form 8-K Beam Therapeutics Inc. For: Dec 08
Low
Report
Form 8-K Beam Therapeutics Inc. For: Dec 08
11/5
11:27 am
beam
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FMR LLC
11/4
07:12 am
beam
Form 10-Q Beam Therapeutics Inc. For: Sep 30
Low
Report
Form 10-Q Beam Therapeutics Inc. For: Sep 30
11/4
07:07 am
beam
Form 8-K Beam Therapeutics Inc. For: Nov 04
Medium
Report
Form 8-K Beam Therapeutics Inc. For: Nov 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/11
Form 8-K Beam Therapeutics Inc. For: Feb 10
14.5%
3/17 Keros Therapeutics on deck for IPO [Seeking Alpha] 12.8%
2/7 Form 424B4 Beam Therapeutics Inc. 9.7%
2/11 Beam Therapeutics Announces Pricing of Initial Public Offering 8.6%
4/28 Beam Therapeutics to Present First Data Highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at 23rd ASGCT Annual Meeting 3.6%
3/4 Beam Therapeutics Inc (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. 3.6%
3/30 Form 10-K Beam Therapeutics Inc. For: Dec 31 2.9%
3/17 Keros Therapeutics on deck for IPO [Seeking Alpha] 12.8%
2/7 Form 424B4 Beam Therapeutics Inc. 9.7%
2/11 Beam Therapeutics Announces Pricing of Initial Public Offering 8.6%
4/28 Beam Therapeutics to Present First Data Highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at 23rd ASGCT Annual Meeting 3.6%
3/4 Beam Therapeutics Inc (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. 3.6%
3/30 Form 10-K Beam Therapeutics Inc. For: Dec 31 2.9%
TOP News Decliners
3/16
Beam Therapeutics Announces Key R&D Appointments
-26.9%
2/5 Form 3 Beam Therapeutics Inc. For: Feb 05 Filed by: Burrell Terry-Ann -21.9%
2/24 Form S-8 Beam Therapeutics Inc. -6.6%
3/5 Form SEC STAFF LETTER Beam Therapeutics Inc. -2.4%
3/30 Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results -0.3%
2/5 Form 3 Beam Therapeutics Inc. For: Feb 05 Filed by: Burrell Terry-Ann -21.9%
2/24 Form S-8 Beam Therapeutics Inc. -6.6%
3/5 Form SEC STAFF LETTER Beam Therapeutics Inc. -2.4%
3/30 Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: